Anesthesia choice during breast surgery may influence cancer return years later
NCT ID NCT07689253
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study follows women who had breast cancer surgery to see if the type of anesthesia they received—propofol or sevoflurane—affects cancer recurrence and survival 5 and 10 years later. Only patients from an earlier trial are included. The goal is to understand whether anesthesia technique can influence long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If a link is found, it could guide anesthesia choices to improve long-term outcomes for breast cancer patients.
- What could go wrong
- This is an observational follow-up, not a new treatment test. Results may show no difference between anesthesia types, and the small size limits general conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
161 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Only patients who participated in the clinical trial (CEC 2016 - 01791) can be included into this study.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Only patients who consented and participated in the trial CEC N° 2016 - 01791 can be enrolled. * GC must be available for patients with follow-up consultations at USZ. * For patients with follow-up consultations outside of the USZ for those with unknown GC status, and for those who declined the GC, a study-specific written informed consent must be obtained, which will allow the research team to contact the responsible physician Exclusion Criteria: * Declined study-specific informed consent * Inability to provide study-specific consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Zurich, Institute of Anesthesiology and Perioperative Medicine
Zurich, Canton of Zurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?